Douglas Onsi Net Worth

The estimated Net Worth of Douglas E Onsi is at least $1.02 Million dollars as of 26 January 2024. Mr. Onsi owns over 7,500 units of Leap Therapeutics Inc stock worth over $203,999 and over the last 8 years he sold LPTX stock worth over $0. In addition, he makes $816,959 as President, Chief Executive Officer, and Director at Leap Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Onsi LPTX stock SEC Form 4 insiders trading

Douglas has made over 4 trades of the Leap Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of LPTX stock worth $20,775 on 26 January 2024.

The largest trade he's ever made was buying 1,057,769 units of Leap Therapeutics Inc stock on 14 November 2017 worth over $6,441,813. On average, Douglas trades about 120,911 units every 119 days since 2017. As of 26 January 2024 he still owns at least 73,646 units of Leap Therapeutics Inc stock.

You can see the complete history of Mr. Onsi stock trades at the bottom of the page.

Douglas Onsi biography

Douglas E. Onsi J.D. serves as President, Chief Executive Officer, Director of the Company. He has served as a member of our Board since March 2020 and as our Chief Executive Officer and President since April 2020. Mr. Onsi also has served as our Chief Financial Officer, Treasurer and Secretary since our inception in January 2011. Mr. Onsi has been at HealthCare Ventures since 2007, including serving as a managing director since 2009 and the chief executive officer of Tensha Therapeutics, Inc., which was sold to Roche Holdings, Inc. in 2016. Prior to joining HealthCare Ventures, Mr. Onsi was at Genzyme Corporation, or Genzyme, where he served in various roles, including as Vice President, Campath Product Operations and Portfolio Management, Oncology from 2005 to 2007 and as Vice President, Business Development from 2004 to 2005. Prior to Genzyme, he was Chief Financial Officer of Tolerx, Inc., a venture capital funded biotechnology company, from 2001 to 2004. Before joining Tolerx, Inc., he was in business development at LeukoSite, a publicly traded biopharmaceutical company that was acquired by Millennium Pharmaceuticals, Inc. He began his career as an attorney at Bingham Dana LLP. Mr. Onsi currently serves as a member of the board of directors of Vaxxas Pty Ltd., a privately-held biotechnology company. He received a Juris Doctor degree from the University of Michigan Law School and a B.S. in biological sciences from Cornell University.

What is the salary of Douglas Onsi?

As the President, Chief Executive Officer, and Director of Leap Therapeutics Inc, the total compensation of Douglas Onsi at Leap Therapeutics Inc is $816,959. There are no executives at Leap Therapeutics Inc getting paid more.

How old is Douglas Onsi?

Douglas Onsi is 51, he's been the President, Chief Executive Officer, and Director of Leap Therapeutics Inc since 2020. There are 8 older and 2 younger executives at Leap Therapeutics Inc. The oldest executive at Leap Therapeutics Inc is James Cavanaugh, 82, who is the Independent Director.

What's Douglas Onsi's mailing address?

Douglas's mailing address filed with the SEC is C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE, MA, 02141.

Insiders trading at Leap Therapeutics Inc

Over the last 8 years, insiders at Leap Therapeutics Inc have traded over $0 worth of Leap Therapeutics Inc stock and bought 10,810,588 units worth $40,517,079 . The most active insiders traders include Advisors Llcperceptive Life..., Christopher Mirabelli, and Ltd. Bei Gene,. On average, Leap Therapeutics Inc executives and independent directors trade stock every 142 days with the average trade being worth of $1,990,710. The most recent stock trade was executed by Christopher Mirabelli on 26 January 2024, trading 5,000 units of LPTX stock currently worth $13,850.

What does Leap Therapeutics Inc do?

leap therapeutics (nasdaq: lptx) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. for more information about leap therapeutics, visit http://www.leaptx.com or our public filings with the sec that are available via edgar at http://www.sec.gov or via http://www.investors.leaptx.com.

Complete history of Mr. Onsi stock trades at Leap Therapeutics Inc

Leap Therapeutics Inc executives and stock owners

Leap Therapeutics Inc executives and other stock owners filed with the SEC include:

• Douglas Onsi,
  President, Chief Executive Officer, Director
• Augustine Lawlor,
  Chief Operating Officer
• Christopher Mirabelli,
  Chairman of the Board
• Cynthia Sirard,
  Chief Medical Officer
• Mark O'Mahony,
  Chief Manufacturing Officer
• Nissim Mashiach,
  Independent Director
• Joseph Loscalzo,
  Independent Director
• William Li,
  Independent Director
• Thomas Dietz,
  Lead Independent Director
• James Cavanaugh,
  Independent Director
• Monica Bertagnolli,
  Independent Director
• John W Littlechild,
  Director
• Ventures Ix, L.P.Healthcare...,
  
• Harold R Werner,
  10% owner
• Lilly & Co Eli,
  10% owner
• Patricia A. Martin,
  Director
• Christian M Richard,
  Director
• Richard Schilsky,
  Director
• Advisors Llcperceptive Life...,
  
• Ventures Viii, L.P.Health C...,
  
• Jason Baum,
  Chief Scientific Officer
• Christine Granfield,
  VP, Head of Reg Affairs/Qual
• Ltd. Bei Gene,,
  10% owner